Affimed N.V Net debt/EBITDA

Qual é o Net debt/EBITDA de Affimed N.V?

O Net debt/EBITDA de Affimed N.V. é 10.32

Qual é a definição de Net debt/EBITDA?



The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.

The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.

Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization

Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.

Net debt/EBITDA de empresas na Setor Health Care em NASDAQ em comparação com Affimed N.V

O que Affimed N.V faz?

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli

Empresas com net debt/ebitda semelhantes a Affimed N.V